RECRUITINGINTERVENTIONAL
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
About This Trial
The goal of this study is to prospectively follow the level of circulating nucleosomes in patients treated for a non-Hodgkin lymphoma and determine whether it correlates with the clinical response.
Who May Be Eligible (Plain English)
Who May Qualify:
- Histologically proven diagnosis of diffuse large B cell lymphoma or follicular lymphoma, according to the WHO 2016 classification, requiring a first line of treatment with a RCHOP 21 regimen
- Agreement to participate after receiving oral and written information on the study
Who Should NOT Join This Trial:
- History of previous treatment for lymphoma (excluding localized low dose radiotherapy in the case of follicular lymphoma)
- Treatment with a chemotherapy regimen different from RCHOP21
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Histologically proven diagnosis of diffuse large B cell lymphoma or follicular lymphoma, according to the WHO 2016 classification, requiring a first line of treatment with a RCHOP 21 regimen
* Agreement to participate after receiving oral and written information on the study
Exclusion Criteria:
* History of previous treatment for lymphoma (excluding localized low dose radiotherapy in the case of follicular lymphoma)
* Treatment with a chemotherapy regimen different from RCHOP21
Treatments Being Tested
BIOLOGICAL
blood sampling
A maximum of 4 tubes of 10ml will be collected: at baseline (before cycle 1), before each cycle (from 2 to 6 included), at the end of the treatment, and in case of relapse during follow-up period
Locations (1)
Gustave Roussy
Villejuif, France